- Home
- RMMZ vs THRD Comparison
RMMZ vs THRD Comparison
Compare RMMZ & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMMZ
- THRD
- Stock Information
- Founded
- RMMZ 2022
- THRD 2019
- Country
- RMMZ United States
- THRD United States
- Employees
- RMMZ N/A
- THRD 53
- Industry
- RMMZ Investment Managers
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- RMMZ Finance
- THRD Health Care
- Exchange
- RMMZ Nasdaq
- THRD Nasdaq
- Market Cap
- RMMZ 133.6M
- THRD 164.2M
- IPO Year
- RMMZ N/A
- THRD 2022
- Fundamental
- Price
- RMMZ $13.99
- THRD $5.16
- Analyst Decision
- RMMZ
- THRD Hold
- Analyst Count
- RMMZ 0
- THRD 3
- Target Price
- RMMZ N/A
- THRD $5.00
- AVG Volume (30 Days)
- RMMZ 25.6K
- THRD 1.1M
- Earning Date
- RMMZ 01-01-0001
- THRD 05-14-2025
- Dividend Yield
- RMMZ 7.33%
- THRD N/A
- EPS Growth
- RMMZ N/A
- THRD N/A
- EPS
- RMMZ 0.82
- THRD N/A
- Revenue
- RMMZ N/A
- THRD N/A
- Revenue This Year
- RMMZ N/A
- THRD N/A
- Revenue Next Year
- RMMZ N/A
- THRD N/A
- P/E Ratio
- RMMZ $19.41
- THRD N/A
- Revenue Growth
- RMMZ N/A
- THRD N/A
- 52 Week Low
- RMMZ $12.92
- THRD $3.18
- 52 Week High
- RMMZ $16.99
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- RMMZ 21.97
- THRD 80.42
- Support Level
- RMMZ $13.98
- THRD $3.30
- Resistance Level
- RMMZ $14.33
- THRD $5.15
- Average True Range (ATR)
- RMMZ 0.35
- THRD 0.16
- MACD
- RMMZ -0.06
- THRD 0.24
- Stochastic Oscillator
- RMMZ 12.66
- THRD 99.47
About RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.